The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2023

Filed:

Oct. 10, 2019
Applicant:

Medtronic, Inc., Minneapolis, MN (US);

Inventors:

Megan Schmidt, Blaine, MN (US);

Lars Mattison, St. Anthony, MN (US);

Assignee:

Medtronic, Inc., Minneapolis, MN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 5/053 (2021.01); A61B 5/00 (2006.01); A61B 18/14 (2006.01); A61B 90/00 (2016.01); A61B 18/00 (2006.01);
U.S. Cl.
CPC ...
A61B 5/053 (2013.01); A61B 5/6853 (2013.01); A61B 18/1492 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00875 (2013.01); A61B 2090/065 (2016.02);
Abstract

A method and system for lesion formation assessment in tissue that has undergone an ablation procedure. In one embodiment, a method of assessing lesion formation comprises: recording a baseline impedance measurement from an area of tissue with a medical device; ablating the area of tissue with the medical device; recording a post-treatment impedance measurement from the area of tissue with the medical device; identifying at least one amplitude characteristic of the baseline impedance measurement and identifying at least one amplitude characteristic of the post-treatment impedance measurement; comparing the at least one amplitude characteristic of the baseline impedance measurement and the at least one amplitude characteristic of the post-treatment impedance measurement; generating an indication of efficacy based on the comparison, the indication of efficacy being one of sufficient lesion formation and insufficient lesion formation; and re-ablating the area of tissue if the indication of efficacy is insufficient lesion formation.


Find Patent Forward Citations

Loading…